JLK1486, a bis 8-hydroxyquinoline-substituted benzylamine, displays cytostatic effects in experimental gliomas through MyT1 and STAT1 activation and, to a lesser extent, PPARγ activation

Translational Oncology

Volumn 4, Issue 3, 2011, Pages 126-137

  Bruyère, Céline ^a   Madonna, Sébastien ^b   van Goietsenoven, Gwendoline ^a   Mathieu, Véronique ^a   Dessolin, Jean ^b   Kraus, Jean Louis ^b   Lefranc, Florence ^a   Kiss, Robert ^a  

^a ERASME HOSPITAL   (Belgium)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL; BENZYLAMINE; JLK 1486; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STAT1 PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MYT1; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR CELL; TUMOR GROWTH;

EID: 79957899285     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10253     Document Type: Article

References (46)

1. Sanai N, Alvarez-Buylla A, and Berger MS (2005). Neural stem cells and the origin of gliomas. N Engl J Med 353, 811-822.
2. Louis DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis 1, 97-117.
3. Lefranc F, Facchini V, and Kiss R (2007). Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12, 1395-1403.
4. Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3, 489-501.
5. Lefranc F, Brotchi J, and Kiss R (2005). Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23, 2411-2422.
6. Sontheimer H (2008). An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood) 233, 779-791.
7. Lefranc F and Kiss R (2008). The sodium pump α-1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 10, 198-206.
8. Ceruti S, Mazzola A, and Abbrachio MP (2005). Resistance of human astrocytomas cells to apoptosis induced by mitochondria-damaging agents: possible implications for anticancer therapy. J Pharmacol Exp Ther 314, 825-837.
9. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
10. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, and Loeffler JS (2006). Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12, 4738-4746.
11. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, and Kondo S (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11, 448-457.
12. Katayama M, Kawaguchi T, Berger MS, and Pieper RO (2007). DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14, 548-558.
13. RoosWP, Batista LFZ,Naumann SC, WickW, Weller M,Menck CFM, and Kaina B (2007). Apoptosis in malignant glioma cells triggered by the temozolomideinduced DNA lesion O6-methylguanine. Oncogene 26, 186-197.
14. Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, and Lefranc F (2008). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392.
15. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, and GilbertMR, (2008). Correlation ofO6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMTactivity. J Clin Oncol 26, 4189-4199.
16. Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe- Kains B, Bontempi G, Decaestecker C, Ruyschaert JM, et al. (2010). Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 12, 727-739.
17. Lamoral-Theys D, Le Mercier M, Le Calvé B, Rynkowski M, Bruyère C, Decaestecker C, Haibe-Kains B, Bontempi G, Dubois J, Lefranc F, et al. (2010). Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia 12, 69-79.
18. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, and Abrey LE (2005). Salvage temozolomide for prior temozolomide responders. Cancer 104, 2473-2476.
19. Furnari FB, Fenton T, Bachoo RM,Mukasa A, Stommel JM, Stegh A, HahnWC, Ligon KL, Louis DN, Brennan C, et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710.
20. Djedid R, Kiss R, and Lefranc F (2009). Targeted therapy of glioblastomas: a 5-year view. Future Med 6, 351-370.
21. Madonna S, Béclin C, Laras Y,Moret V,Marcowycz A, Lamoral-Theys D, Dubois J, Barthelemy-Requin M, Lenglet G, Depauw S, et al. (2010). Structure-activity relationships and mechanism of action of antitumor bis 8-hydroxyquinoline substituted benzylamines. Eur J Med Chem 45, 623-638.
22. Wang P, Song Y, Zhang L, He H, and Zhou X (2005). Quinone methide derivatives: important intermediates to DNA alkylating and DNA cross-linking actions. Curr Med Chem 12, 2893-2913.
23. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, and Salmon I (2002). Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95, 641-655.
24. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. (2009). Galectin-1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11, 485-496.
25. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius HJ, and Kiss R (2005). Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenograft. J Neurosurg 102, 706-714.
26. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, et al. (2009). Structure-activityrelationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril alkaloid) as potential anti-cancer agents. J Med Chem 52, 1100-1114.
27. Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, et al. (2008). Targeting the α-1 subunit of the sodium pump (the Na+/K+-ATPase) to combat glioblastoma cells. Neurosurgery 62, 211-222.
28. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, and Kiss R (2007). Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J InvestDermatol 127, 2399-2410.
29. Debeir O, Mégalizzi V, Warzée N, Kiss R, and Decaestecker C (2008). Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res 314, 2985-2998.
30. Lamoral-Theys D, Pottier L, Kerff F, Dufrasne F, Proutière F, Wauthoz N, Neven P, Ingrassia L, Van Antwerpen P, Lefranc F, et al. (2010). Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. BioOrg Med Chem 18, 3823-3833.
31. Mathieu V, Mijatovic T, Van Damme M, and Kiss R (2005). Gastrin exerts pleitropic effects on human melanoma cell biology. Neoplasia 7, 930-943.
32. Trott O and Olson AJ (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461.
33. Sanner MF (1999). Python: a programming language for software integration and development. J Mol Graphics Mod 17, 57-61.
34. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, and Tweardy DJ (2009). Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 4(3), e4783.
35. Ondrey F (2009). Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15, 2-8.
36. Moret V, Laras Y, Cresteil T, Aubert G, Di QPDC, Barthelemy-Requin M, Beclin C, Peyrot V, Allegro D, Rolland A, et al. (2009). Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: synthesis, structure-activity relationship, and action mechanism studies. Eur J Med Chem 44, 558-567.
37. eufert S, Coras R, Tränkle C, Zlotos DP, Blümcke I, Tatenhorst L, Heneka MT, and Hahnen E (2008). PPARγ activators: off-target against glioma cell migration and brain invasion. PPAR Res 2008, 513943.
38. Grommes C, Landreth GE, Schlegel U, and Heneka MT (2005). The nonthiazolinidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther 313, 806-813.
39. Strakova N, Ehrmann J, Dzubak P, Bouchal J, and Kolar Z (2004). The synthetic ligand of peroxisome proliferator-activated receptor-γ ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 309, 1239-1247.
40. Potapova TA, Daum JR, Byrd KS, and Gorbsky GJ (2009). Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Mol Biol Cell 20, 1737-1748.
41. Wang Y, Decker SJ, and Sebolt-Leopold J (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3, 305-313.
42. Kim HS and Lee MS (2007). STAT1 as a key modulator of cell death. Cell Signal 19, 454-465.
43. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, WangW, McMurray JS, Demeler B, Darnell JE Jr, and Chen X (2005). Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17, 761-771.
44. Regis G, Pensa S, Boselli D, Novelli F, and Poli V (2008). Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signaling. Sem Cell Dev Biol 19, 351-359.
45. Gunning PT, Katt WP, Glenn M, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, and Hamilton AD (2007). Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett 17, 1875-1878.
46. Atkinson GP, Nozell SE, and Benveniste ET (2010). NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 10, 575-586.